{"id":543292,"date":"2021-05-14T16:28:01","date_gmt":"2021-05-14T16:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543292"},"modified":"2021-05-14T16:28:01","modified_gmt":"2021-05-14T16:28:01","slug":"polycystic-ovary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dexa-medica-astellas-effrx-spruce-biosciences-neurocrine-biosciences-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/polycystic-ovary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dexa-medica-astellas-effrx-spruce-biosciences-neurocrine-biosciences-and-others_543292.html","title":{"rendered":"Polycystic Ovary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Dexa Medica, Astellas, EffRx, Spruce Biosciences, Neurocrine Biosciences and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620962778.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Polycystic Ovary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Dexa Medica, Astellas, EffRx, Spruce Biosciences, Neurocrine Biosciences and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620962778.jpeg\" alt=\"Polycystic Ovary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Dexa Medica, Astellas, EffRx, Spruce Biosciences, Neurocrine Biosciences and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Polycystic Ovary Syndrome Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Polycystic ovary syndrome<\/strong> (PCOS) is a condition that affects a woman&rsquo;s hormone levels. Polycystic ovary syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health and appearance. PCOS is also a common and treatable cause of infertility.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/polycystic-ovarian-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Polycystic ovary syndrome Pipeline<\/a><\/strong><strong> Insight, 2021<\/strong>&rdquo; report provides comprehensive insights about <strong>8+ companies and 8+ pipeline drugs<\/strong> in Polycystic ovary syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Polycystic Ovary Syndrome Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Dexa Medica<\/li>\n<li>Astellas<\/li>\n<li>EffRx<\/li>\n<li>Spruce Biosciences<\/li>\n<li>Neurocrine Biosciences<\/li>\n<li>Fractyl Laboratories<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/polycystic-ovarian-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/polycystic-ovarian-syndrome-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Polycystic Ovary Syndrome report covers around 8+ products under different phases of clinical development like:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/polycystic-ovarian-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Polycystic Ovary Syndrome Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DLBS3233<\/li>\n<li>Fezolinetant<\/li>\n<li>Metformin effervescent<\/li>\n<li>Elagolix<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/polycystic-ovarian-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/polycystic-ovarian-syndrome-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Polycystic Ovary Syndrome Treatment Scenario and Polycystic Ovary Syndrome Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Polycystic ovary syndrome drugs?<\/li>\n<li>How many Polycystic ovary syndrome drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovary syndrome?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovary syndrome therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Polycystic ovary syndrome and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/polycystic-ovarian-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/polycystic-ovarian-syndrome-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">DLBS3233: Dexa Medica<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Elagolix: Abbvie\/ Neurocrine Biosciences<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early stage products (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome Key Products<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome Analyst Views<\/p>\n<p style=\"text-align: justify;\">Polycystic ovary syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/polycystic-ovarian-syndrome-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=polycystic-ovary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dexa-medica-astellas-effrx-spruce-biosciences-neurocrine-biosciences-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/polycystic-ovarian-syndrome-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/polycystic-ovarian-syndrome-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/polycystic-ovarian-syndrome-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=polycystic-ovary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dexa-medica-astellas-effrx-spruce-biosciences-neurocrine-biosciences-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polycystic Ovary Syndrome Pipeline Polycystic ovary syndrome (PCOS) is a condition that affects a woman&rsquo;s hormone levels. Polycystic ovary syndrome (PCOS) is a health problem that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/polycystic-ovary-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-dexa-medica-astellas-effrx-spruce-biosciences-neurocrine-biosciences-and-others_543292.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-543292","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543292"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543292\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}